Nexium 24HR is the second OTC proton pump inhibitor available in the US to add a label warning about a potential risk of rare skin reaction, a change firms marketing generic equivalents also are expected to make.
The FDA Center for Drug Evaluation and Research
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?